Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroesophageal Reflux Disease: early-phase trial registry
4 of 26 indexed Gastroesophageal Reflux Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · 4 currently recruiting · #627 of 28,707 conditions by registered trial count
Gastroesophageal Reflux Disease: 26 US clinical trials tracked, 4 recruiting.
Gastroesophageal Reflux Disease is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 3 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-reflux-disease
OPEN 4 | RECR 15% | LATE 2 | EARLY 11 | RANK #627 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Arthroplasty, Replacement, Knee (15% recruiting · 13 trials)
Gastroesophageal Reflux Disease lists 4 open slots (15% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroesophageal Reflux Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroesophageal Reflux Disease is recruiting below its size-band peers.
4 of 26 indexed trials (15.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastroesophageal Reflux Disease trials is spread across many organizations.
Takeda accounts for 3 of 26 trials (11.5%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroesophageal Reflux Disease enrolment sits around 104 participants.
Median target enrolment is 104 among the 26 trials that report a genuine target (sentinel values excluded). 13 of those (50%) plan for fewer than 100 participants.
-
Gastroesophageal Reflux Disease research is mostly interventional.
19 interventional and 7 observational studies make up this index (73.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
26 total, page 1 of 1
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
Midwest Biomedical Research Foundation
NCT00574327
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
University of Colorado, Denver
NCT06693622
Domperidone in Treating Patients With Gastrointestinal Disorders
M.D. Anderson Cancer Center
NCT01696734
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
University of California, Irvine
NCT06783751
Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease
University of Pittsburgh
NCT00260572
Transoral Fundoplication Prior to Sleeve Gastrectomy Versus RNY Gastric Bypass on GERD Symptoms in Bariatric Patients
Lexington Health Incorporated
NCT05365087
Morphological Markers of Gastroesophageal Reflux Disease (GERD)
Baylor College of Medicine
NCT01921686
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison
NCT05107219
Economic Impact of Guidelines for Gastroesophageal Reflux Disease
US Department of Veterans Affairs
NCT00057174
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Shire
NCT01472939
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
Ironwood Pharmaceuticals
NCT02637557
Maintenance Intermittent Therapy for Symptomatic GERD Patients
Eisai
NCT00165841
Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study
EndoGastric Solutions
NCT01136980
Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures
Swedish Medical Center
NCT01260935
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
Eisai
NCT00132496
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
Takeda
NCT01642602
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
Associated Scientists to Help Minimize Allergies
NCT00214552
Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital
University of Nebraska
NCT01776827
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
Takeda
NCT01642615
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Mayo Clinic
NCT00728481
Esophageal Cytology With FISH in Detecting Esophageal Cancer
OHSU Knight Cancer Institute
NCT02100189
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
Eisai Co.
NCT01390714
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
University of North Carolina, Chapel Hill
NCT02226484
Gastric Bypass After Previous Anti-reflux Surgery
University of California, San Francisco
NCT01041105
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
OHSU Knight Cancer Institute
NCT02890979
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
Takeda
NCT02096458
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroesophageal Reflux Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroesophageal Reflux Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroesophageal Reflux Disease page
26 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Gastroesophageal Reflux Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Takeda sponsors the most Gastroesophageal Reflux Disease trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroesophageal Reflux Disease condition card totals 26 registered trials; most-linked intervention Dexlansoprazole; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.